Valeant Pharmaceuticals Intl Inc VRX shares are off almost 50 percent on Tuesday after the company issued poor earnings and guidance, all while reaffirming the SEC is still probing its operations. Ex-pharma exec-turned hedge fund manager-turned FBI fraud target Martin Shkreli is analyzing the company, live on his YouTube channel.
As several comments point out, Shkreli is going through Valeant's financials on Microsoft Excel, talking everything from Philidor to drug sales.
Valeant shares appear unaffected by Shkreli's commentary. The broadcast concludes at 4 p.m. ET; the full broadcast is expected to be replayable then.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
